Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck effective Tax Rate Benefit from R&D Tax Credits (percentage points) (%)
Form 10-K Taxes on Income Note
Latest, FY2025
1.2%
Period ended Dec 31, 2025
Change on a year earlier
+0.2 pts
1.0% in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Effective Tax Rate Benefit from R&D Tax Credits (percentage points) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.2% | +0.2 pts | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1.0% | -10.3 pts | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 11.3% | +10.6 pts | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 0.7% | -0.1 pts | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 0.8% | -1.0 pts | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 1.8% | +0.2 pts | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 1.6% | +0.5 pts | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 1.1% | 0.0 pts | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 1.1% | -0.2 pts | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 1.3% | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). Merck Effective Tax Rate Benefit from R&D Tax Credits (percentage points) (%), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/tax_rd_credit_pct
See every metric in the Merck KPI table. Data updated Oct 26, 2026.